Vertex Pharmaceuticals Incorporated Stock

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:16:47 2024-05-14 pm EDT 5-day change 1st Jan Change
426.9 USD -0.71% Intraday chart for Vertex Pharmaceuticals Incorporated +3.91% +4.76%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 10.75B Sales 2025 * 11.67B Capitalization 111B
Net income 2024 * 3.99B Net income 2025 * 4.46B EV / Sales 2024 * 9.02 x
Net cash position 2024 * 13.97B Net cash position 2025 * 19.01B EV / Sales 2025 * 7.88 x
P/E ratio 2024 *
28.3 x
P/E ratio 2025 *
25.1 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.89%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vertex Pharmaceuticals Incorporated

1 day-1.61%
1 week+3.31%
Current month+7.89%
1 month+6.66%
3 months+1.42%
6 months+14.56%
Current year+4.16%
More quotes
1 week
412.12
Extreme 412.12
430.52
1 month
391.01
Extreme 391.01
430.52
Current year
391.01
Extreme 391.01
448.40
1 year
320.01
Extreme 320.01
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
164.96
Extreme 164.96
448.40
10 years
63.60
Extreme 63.6
448.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 17-01-31
Chairman 68 09-07-07
Director of Finance/CFO 55 19-04-09
Members of the board TitleAgeSince
Director/Board Member 68 17-06-07
Chairman 68 09-07-07
Director/Board Member 64 97-12-31
More insiders
Date Price Change Volume
24-05-14 426.3 -0.84% 424 562
24-05-13 429.9 +1.69% 939,753
24-05-10 422.8 +0.90% 1,064,604
24-05-09 419 +0.04% 676,185
24-05-08 418.8 +2.09% 1,651,673

Delayed Quote Nasdaq, May 14, 2024 at 11:53 am EDT

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
429.9 USD
Average target price
462.6 USD
Spread / Average Target
+7.59%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW